Get the Stockscreener App
7.46
4.66%
-0.365
Novavax Inc stock is traded at $7.46, with a volume of 3.17M.
It is down -4.66% in the last 24 hours and down -16.18% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$7.825
Open:
$7.9
24h Volume:
3.17M
Relative Volume:
0.68
Market Cap:
$1.23B
Revenue:
$596.34M
Net Income/Loss:
$-87.84M
P/E Ratio:
-12.49
EPS:
-0.5975
Net Cash Flow:
$-97.62M
1W Performance:
-9.14%
1M Performance:
-16.18%
6M Performance:
-18.65%
1Y Performance:
-2.36%
1-Day Range:
$7.45
$7.9299
1-Week Range:
$7.45
$8.30
52-Week Range:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.46 | 1.23B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
NVAX|Novavax Inc|Price:7.460|Chg%:-0.365 - TradingKey
Novavax Inc (NVAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax Inc (NVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Novavax, Inc. Revenue Breakdown – NASDAQ:NVAX - TradingView
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Inc (NVAX) Fundamental & Financial Data - Stocktwits
(NVAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax Inc (NVAX) Institutional Confidence - TradingKey
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax Inc. Stock Sheds 4.0%, Underperforms Peers - webull.com
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. (NVAX) Stock Analysis: Potential Upside of 79.10% Amidst Challenging Financial Metrics - DirectorsTalk Interviews
NVAX Stock Is Rising Even After A Revenue Collapse – Here’s The Catch - Stocktwits
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
NVAX stock trades in a wide range as Novavax works through Covid vaccine transition - AD HOC NEWS
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Robert Edward Walker Net Worth (2026) - GuruFocus
Novavax options trading jumps to highest in months By Investing.com - Investing.com Nigeria
Novavax options trading jumps to highest in months - Investing.com
Enterprise value to EBIT forward of Novavax, Inc. – BMV:NVAX - TradingView
Novavax, Inc. (NVAX) is a trending stock: Facts to know before betting on it - MSN
Novavax (NVAX) Leaves Russell Growth Indexes, Is The 32% Undervaluation Case Convincing? - Yahoo Finance
Novavax (NVAX) Dropped From Major Russell Growth Indices And Why It Matters - Yahoo Finance
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Novavax Inc. stock outperforms competitors despite losses on the day - MarketWatch
Novavax Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Novavax Inc updates Covid-19 vaccine plans as investors weigh long-term prospects - ad-hoc-news.de
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study - TradingView
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Does Novavax’s (NVAX) Russell Exit Quietly Recast Its Partnership-Driven, Royalty-Focused Equity Story? - Sahm
NOVAVAX INC (NVAX) Stock Chart - ChartMill
Novavax (NVAX) Stock Moves 1.36%: What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
(NVAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Novavax, Inc.(NasdaqGS: NVAX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
ETFs Investing in Novavax, Inc. Stocks - TradingView
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):